Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04729816 · ClinicalTrials.gov registry record · NA

Assessing the Dose Response of a Lead Fiber Snack Prototype

A NA study of Microbiota and Gastrointestinal Microbiome, sponsored by Washington University School of Medicine.

Completed
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT04729816: Completed NA study of Microbiota and Gastrointestinal Microbiome, sponsored by Washington University School of Medicine.

NCT04729816 is a NA study of Microbiota and Gastrointestinal Microbiome that has completed, run by Washington University School of Medicine. The registered enrollment target is 17 participants, below the 138-participant average among 10 other Microbiota trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04729816, a NA study of Microbiota and Gastrointestinal Microbiome, has completed, sponsored by Washington University School of Medicine.

COMPLETED
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

Aim: To test the effects of a fiber-blend containing snack prototype in an escalating dose regimen (from 1 to 3 servings per day over a period of 6 weeks) on the configuration and gene content of the gut microbiota of overweight and obese participants (BMI 25-35 kg/m2), while consuming a controlled diet that contains quantities of saturated fats in the upper tertile and quantities of fruits and vegetables in the lower tertile of consumption in the NHANES database (high saturated fat-low fruit and vegetable; HiSF-LoFV). Changes in the representation of bacterial genes involved in carbohydrate utilization in the microbiomes of participants will be correlated with changes in plasma biomarkers at the end of each escalating dose phase by comparing features of their pre- vs post-treatment plasma proteomes and metabolomes. Design: Participants will be asked to continue to consume their habitual diet (free diet phase) for 1 day prior to being provided with a HiSF-LoFV diet in the form of packed-out meals and snacks to consume for the following 62 days. Ten days after starting to consume the HiSF-LoFV diet, participants will supplement this diet with a fiber-blend containing snack (\~10g fiber/serving) once daily for a total of 14 days; the energy contribution from the HiSF-LoFV diet will be reduced accordingly to maintain energy needs during this time and the remainder of the study. For the next 14 days, the diet will be supplemented with two of the same fiber-blend containing snacks per day, followed by 14 days in which the snacks will be consumed three times daily. Subsequently, a 'wash-out' phase of ten days in which the HiSF-LoFV diet is consumed without any of fiber snack supplementation will conclude the study. Stool, urine and blood will be sampled periodically throughout.

Primary Outcome

Changes to the gut microbiota/microbiome as a function of background diet and fiber dose escalation using culture independent methods. Investigators will use higher order singular value decomposition (HOSVD) to analyze changes in the gut microbiome - including the representation of carbohydrate-active enzyme genes (CAZymes), metabolic pathways and Amplicon Sequence Variants (ASVs) in shotgun sequencing datasets generated from fecal DNA collected at the beginning and end of each dose escalation p

Interventions

  • OTHER Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food.

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2021-02-22
Est. Completion 2021-11-15
Phase NA

What the finished NCT04729816 record still lists

NCT04729816 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 17 participants, a relatively small participant target, below the 138-participant average among 10 other Microbiota trials with a reported enrollment target (88% lower).

The record links to 2 conditions, with Microbiota appearing as the primary indexed condition, and to 1 intervention - of which Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food. is the first listed.

NCT04729816 reports a single indexed study location in Missouri.

Frequently Asked Questions

What is clinical trial NCT04729816 about?

NCT04729816 is a clinical study titled "Assessing the Dose Response of a Lead Fiber Snack Prototype". Aim: To test the effects of a fiber-blend containing snack prototype in an escalating dose regimen (from 1 to 3 servings per day over a period of 6 weeks) on the configuration and gene content of the gut microbiota of overweight and obese participants (BMI 25-35 kg/m2), while consuming a controlled ...

What is the current status of trial NCT04729816?

This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2021-02-22. Estimated completion is 2021-11-15.

What conditions does trial NCT04729816 study?

This clinical trial studies the following conditions: Microbiota, Gastrointestinal Microbiome.

What interventions are being tested in trial NCT04729816?

The interventions under investigation include: Controlled, high fat/low fiber diet background diet, sequentially supplemented with an escalating dose of a fiber-blend snack food. (OTHER).

Who is sponsoring clinical trial NCT04729816?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04729816 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Microbiota

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04729816's enrollment target sits among peer trials

17 11th of 10 the lowest of 10 other Microbiota trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Microbiota trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02090140 · 17 participants · NA

    Microfracture Versus Adipose Derived Stem Cells for the Treatment of Articular Cartilage Defects

  • NCT03317860 · 17 participants · NA

    Improving Measurement and Treatment of Post-stroke Neglect

  • NCT04356469 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Non-Malignant Hematological Disorders in Children

  • NCT04414046 · 17 participants · Phase 2

    TCR Alpha Beta T-cell Depleted Haploidentical HCT in the Treatment of Primary Immunodeficiency and Inherited Metabolic Disorders in Children

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04729816, the US trial registry maintained by the National Library of Medicine. NCT04729816 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.